DIA to host Patient Recruitment and Retention Forum April 20-21, 2009

Executive-level management from biopharma and device sponsors, CROs, consultants, and enrollment services providers will convene at the Drug Information Association's (DIA's) Realizing Structural Change Management for Patient Recruitment Success Forum (April 20 - 21, 2009; Horsham, PA).

ShareThis Email PDF Print

DIA Logo

This unique forum will closely examine the compelling reasons for a paradigm shift in the strategic recruitment planning process, with a focus on how to move away from cost and quantity drivers to process, quality, training, and efficiency driven down through organizations from a strategic level

horsham, PA (Vocus) February 26, 2009

Executive-level management from biopharma and device sponsors, CROs, consultants, and enrollment services providers will convene at the Drug Information Association's (DIA's) Realizing Structural Change Management for Patient Recruitment Success Forum (April 20 - 21, 2009; Horsham, PA).

Patient recruitment and retention is widely recognized as the leading bottleneck in the new drug development pipeline, and it is likely to remain an area of heightened concern for the next several years. As the recruiting culture becomes more sophisticated with the involvement of multiple service vendors and the forces affecting patient enrollment grow more numerous and complex, companies are striving to discover new strategies to facilitate enrollment in clinical trials.

This special DIA forum will address:

Why strategic reinvention of the planning, funding, and site- level processes to recruit and retain participants for all clinical trials is necessary and crucial for future compound development success.
Why improved recruitment and retention performance is integral to successfully navigating the mandate for change facing biopharma Sponsor and CRO leadership with implications such as:

o    Predictable patient recruitment leading to evaluable data remaining a critical driver for successful study completion;
o    Timely delivery of new products to market as a crucial driver of a pharmaceutical company's stock valuation;
o    The significance of downsizing middle management, portfolio reduction and reallocation, and site initiation to developing and redeveloping countries.

"This unique forum will closely examine the compelling reasons for a paradigm shift in the strategic recruitment planning process, with a focus on how to move away from cost and quantity drivers to process, quality, training, and efficiency driven down through organizations from a strategic level," says Program Chairperson John Needham, Global Strategist and Chief Executive Officer, Needham and Company.

Sponsors, CROs, service providers, and clinical research team thought leaders will lead interactive group discussions to further crystallize the topics discussed in the more formal sessions.

About the Drug Information Association (DIA)
DIA serves more than 30,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit http://www.diahome.org or call 215-442-6100.

###